SAMSUNG BIOLOGICS CO.,LTD. KRW 93.5 billion drug contract manufacturing deal with a European drugmaker
SAI summary · Not investment advice
SAMSUNG BIOLOGICS CO.,LTD. signed a KRW 93.5 billion contract manufacturing agreement with a European pharmaceutical company, equal to 2.05% of recent revenue.
Contract amount
KRW 93.5 billion
2.05% of recent revenue · fixed amount of USD 68,754,502 converted at USD/KRW 1,359.60
Key facts
- Contract details
- Drug contract manufacturing agreementOther sales/supply contract · voluntary disclosure
- Recent revenue
- KRW 4.6 trillion2025 consolidated
- % of revenue
- 2.05%
- Counterparty
- A European pharmaceutical company
- Contract period
- Oct 2, 2026 – Dec 31, 2031End date may change by mutual agreement
- Contract date
- Oct 2, 2026
- Disclosure deferral
- Counterparty name withheldUntil 2031.12.31 for confidentiality, subject to change
Commentary
AI commentary · Not investment advice
What happened
SAMSUNG BIOLOGICS CO.,LTD. signed a contract to manufacture drugs for a pharmaceutical company based in Europe (contract manufacturing). The contract is worth KRW 93.5 billion. This is the fixed amount of USD 68,754,502 converted at USD/KRW 1,359.60 on the contract date.
In the company's terms
The amount equals 2.05% of recent revenue (KRW 4.6 trillion, 2025 consolidated). The contract runs until 2031.12.31, and the end date may change if both sides agree.
What changes for shareholders
The company withheld the counterparty's name for confidentiality. It plans to disclose the name on 2031.12.31, and that date may also change.
Earlier Single Sales/Supply Contract filings from this company
| Filed | Counterparty | Contract amount | % of revenue |
|---|---|---|---|
| 26.09.102026.09.10 | A pharmaceutical company based in the United States | KRW 62.8 billion | 8.95% |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist